ajones, Author at ASH Clinical News

Home Authors Posts by ajones

328 POSTS 0 COMMENTS

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

Sunday, September 1, 2019

$AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma$

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

Monday, July 15, 2019

Can Women With CML Safely Continue TKIs During Pregnancy?

Saturday, June 15, 2019

$Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL$

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Saturday, June 15, 2019

$Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia$

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

Saturday, June 15, 2019

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Monday, June 10, 2019

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...

Monday, June 10, 2019

$Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma$

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Monday, June 3, 2019

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

Monday, June 3, 2019

New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients

Monday, June 3, 2019

12 3...33 Page 1 of 33

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

Friday, July 16, 2021

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Block title

$3.5 Trillion Proposal by Senate Democrats Includes Drug Pricing Provisions to Offset Spending

Friday, July 23, 2021

FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease

Friday, July 23, 2021

What Will Telehealth Look Like Post-Pandemic?

Friday, July 23, 2021

Pain, Comorbidities Increase Risk of Severe COVID-19 in Patients with SCD

Tuesday, July 20, 2021

Mark A. Crowther, MD

Tuesday, July 20, 2021

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

July 2021 Volume 7 Issue 8

June 2021 Volume 7 Issue 7

May 2021 Volume 7 Issue 6

ajones

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

Can Women With CML Safely Continue TKIs During Pregnancy?

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

Block title

$3.5 Trillion Proposal by Senate Democrats Includes Drug Pricing Provisions to Offset Spending

FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease

What Will Telehealth Look Like Post-Pandemic?

Pain, Comorbidities Increase Risk of Severe COVID-19 in Patients with SCD

Mark A. Crowther, MD

Meeting Coverage

Researchers Validate Burkitt Lymphoma Prognostic Index

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Editor's Corner

Sex Cells: The Forgotten Biological Variable

Editor’s Corner: A Shock in Paradise